Collegium Pharmaceutical, Inc (COLL) stock
Close on Nov 11, 2026Market cap $807.71MP/E 24.8Yield –
Collegium Pharmaceutical, Inc grew revenue 7.7% to $815.19M over the twelve months to Sep 30, 2026. Operating income fell 21.0% to $124.07M, moving the operating margin from 20.7% to 15.2%. Free cash flow was $336.29M, up 16.2% from a year earlier. At the latest close the market valued the company at $807.71M, 24.8 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $807.71M
- P/E ratio
- 24.8
- Price to sales
- 0.99
- Price to book
- 2.72
- Dividend yield
- –
- Free cash flow yield
- 41.63%
Fundamentals
- Revenue
- $815.19M
- Net income
- $38.17M
- EPS, diluted
- $1.00
- Free cash flow
- $336.29M
- Book value per share
- $7.58
- Diluted shares
- 39M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $24.47
- Open
- $24.13
- Day's range
- $23.99 – $24.83
- Volume
- 500,401
- Average volume (20 days)
- 671,087
- Index membership
- S&P SmallCap 600 (since Feb 2021), Russell 2000, Russell 3000
- Beta (5 years)
- 0.46
- 52-week range
- $21.43 – $50.79
- RSI (14 days)
- 60.4
- Volatility (1 year)
- 42.2%
- Relative volume
- 0.69×
- WACC
- 7.4%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | COLL | S&P 500 | Difference | COLL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +12.3% | -2.4% | +14.7 pts | ||
| 3 months | -4.5% | -1.2% | −3.4 pts | ||
| Year to date | -46.4% | +12.3% | −58.7 pts | ||
| 1 year | -44.7% | +12.4% | −57.1 pts | ||
| 3 years | +1.3% | +78.8% | −77.5 pts | +0.4% | +21.4% |
| 5 years | +23.3% | +75.2% | −51.9 pts | +4.3% | +11.9% |
| 10 years | +41.8% | +311.1% | −269.3 pts | +3.6% | +15.2% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Collegium Pharmaceutical filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Results
About Collegium Pharmaceutical
Pharmaceutical Preparations
Collegium Pharmaceutical, Inc. is a commercial-stage biopharmaceutical company that develops and markets medicines for serious conditions, specifically attention deficit hyperactivity disorder and pain management. The company’s portfolio includes Jornay PM, an evening-dosed central nervous system stimulant indicated for patients six years of age and older with ADHD, and Symproic for opioid-induced constipation. Its pain portfolio also includes prescription opioid analgesics such as Xtampza ER, Belbuca, and Nucynta extended-release and immediate-release formulations. The company distributes its prescription products primarily to wholesalers, which supply retail pharmacies, managed health care organizations, and government agencies.
Company profile, executives and historyCollegium Pharmaceutical stock: common questions
What is Collegium Pharmaceutical's stock price?
COLL closed at $24.81 on Nov 11, 2026, up 1.39% on the day. Over the past 52 weeks it traded between $21.43 and $50.79.
What is Collegium Pharmaceutical's market cap?
Collegium Pharmaceutical was worth $807.71M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is COLL's P/E ratio?
COLL trades at 24.8 times earnings, based on diluted earnings per share of $1.00 over the twelve months to Sep 30, 2026.
How much revenue does Collegium Pharmaceutical make?
Collegium Pharmaceutical reported revenue of $815.19M for the twelve months to Sep 30, 2026, up 7.7% from a year earlier.
Does Collegium Pharmaceutical pay a dividend?
No. Collegium Pharmaceutical has not paid a cash dividend over the last twelve months.
When does Collegium Pharmaceutical report earnings next?
Collegium Pharmaceutical is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has COLL stock performed over the past year?
Including dividends, COLL returned -44.7% over the past year, against +12.4% for the S&P 500.
How many COLL shares are sold short?
5M shares were sold short at the latest FINRA report, 16.68% of the float, or 9.4 days of average trading volume.
Who are Collegium Pharmaceutical's competitors?
Companies most similar to Collegium Pharmaceutical by business, industry and size include ACAD, HRMY, AXSM, ANIP, MIRM.
See a number that looks wrong?